Semaglutide reduces systolic blood pressure by 5–8 mmHg on average through weight loss and improved insulin sensitivity—beyond what weight reduction alone

Semaglutide NAFLD treatment shows 59% NASH resolution versus 17% placebo in clinical trials, targeting liver inflammation through mechanisms beyond weight

Semaglutide cancer risk research shows no causal link in humans — animal thyroid tumor data doesn’t translate to clinical use. Here’s what matters.

Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies — but human clinical trials show no confirmed cases. Here’s what

Semaglutide carries a black box warning for thyroid C-cell tumor risk. Understand who should avoid GLP-1 therapy and what the evidence actually shows.

Semaglutide reduces chronic inflammation by lowering inflammatory cytokines IL-6 and TNF-alpha while improving insulin sensitivity and endothelial

Semaglutide reduces liver fat by 30–40% in clinical trials through weight loss and direct anti-inflammatory effects — not through metabolism alone.

Semaglutide 5mg represents a mid-range therapeutic dose — typically reached 8–12 weeks into titration and maintained long-term for sustained metabolic

Semaglutide’s lowest dose (0.25mg) isn’t therapeutic—it’s a tolerance-building step that reduces nausea during titration to the effective 1.7mg or 2.4mg